As of Oct 25
| -0.53 / -1.42%|
The 16 analysts offering 12-month price forecasts for Alnylam Pharmaceuticals Inc have a median target of 50.50, with a high estimate of 137.00 and a low estimate of 34.00. The median estimate represents a +37.71% increase from the last price of 36.67.
The current consensus among 17 polled investment analysts is to Buy stock in Alnylam Pharmaceuticals Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.